# The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea

> **NCT01133431** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 24 (estimated)

## Conditions studied

- Healthy Male Volunteer

## Interventions

- **DRUG:** CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet
- **DRUG:** CKD-501 placebo tablet, Glimepiride 4 mg tablet

## Key facts

- **NCT ID:** NCT01133431
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2010-06
- **Final completion:** 2010-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2010-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01133431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01133431, "The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01133431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*